Clinical Trial Update: Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial comparing pharmacokinetics, safety, and immunogenicity of Biocon Biologics' Bmab1700 versus Opdivo (nivolumab) as adjuvant monotherapy in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Bmab1700
• OPDIVO (nivolumab)

Snippet

Sponsor: Biocon Biologics UK PLC | Conditions: Melanoma | Phase 1 | Status: NOT_YET_RECRUITING